viralic
Forumer storico
Ultima modifica:
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
elfrancese
Forumer storico
c'est insoignable la blepharite...
je n'ai pas assez de culture ophtalmologique pour connaitre la robustesse des résultats en dry eye de nicox, mais le marché me semble beaucoup mieux etabli..
esperons qu'ocumension ait envie de participer ...
et surtout esperons que cette descente aux enfers se terminent rapidement ... car à 100M ca n'a plus aucun sens
sensorion valorise 60M en ayant annonce un echec en phase 2 de leur unique molecule restante en phase clinique !
en tout cas, je ne lache aucun titres meme si je suis de moins en moins en confiance avec mon PRU a 2,99
je n'ai pas assez de culture ophtalmologique pour connaitre la robustesse des résultats en dry eye de nicox, mais le marché me semble beaucoup mieux etabli..
esperons qu'ocumension ait envie de participer ...
et surtout esperons que cette descente aux enfers se terminent rapidement ... car à 100M ca n'a plus aucun sens
sensorion valorise 60M en ayant annonce un echec en phase 2 de leur unique molecule restante en phase clinique !
en tout cas, je ne lache aucun titres meme si je suis de moins en moins en confiance avec mon PRU a 2,99
Jazalde
Forumer storico
Compra ancora hai voglia a mediare di questo passo le prendi anche sotto i due euro
elfrancese
Forumer storico
While the Phase IIb Mississippi study in patients with acute exacerbations of blepharitis did not meet the primary endpoints in that indication, a post-hoc analysis showed potentially promising data that NCX-4251 could provide clinical benefit in patients with dry eye disease (DED), a c $5bn market. Given that blepharitis is commonly associated with DED, of the 224 enrolled patients, 123 were found to have inferior corneal staining (by a score of at least two on a five-point scale), a key sign of DED. Among these 123 patients, there was a statistically significant difference versus placebo in the change from baseline in eye dryness scores (assessed on a validated Visual Analog Scale). Significant differences were also observed in other DED symptoms (including photophobia, blurred vision, burning/stinging, pain and others) at all measured time points in the 14-day treatment, and for some, the effects persisted for up to two weeks after the end of treatment. The company plans to meet the FDA in early 2022 to discuss a potential alternate development path for NCX-4251.
While top-line Mississippi data did not meet the primary endpoints, the recently announced post-hoc data provide potential promise in patients with acute exacerbations of DED. We await further guidance before revisiting our estimates on NCX-4251 but we believe it could be possible, based on FDA feedback, for the company to shift the NCX-4251 development focus from acute exacerbations of blepharitis, to acute exacerbations of DED. It is not surprising a corticosteroid-based product such as NCX-4251 could provide benefit for DED, given that inflammation is a well-known contributor to the disease, and we note that Eyesuvis, a formulation of corticosteroid loteprednol, was approved in Q420 for the short-term treatment of DED. The DED market could provide a substantial opportunity for NCX-4251, as this market is estimated to be worth c $5bn worldwide by Research and Markets and Fortune Business Insights, and three drugs (Restasis, Xiidra and Cequa) have been estimated to account for c $1.5bn in combined total revenue.
www.edisongroup.com
While top-line Mississippi data did not meet the primary endpoints, the recently announced post-hoc data provide potential promise in patients with acute exacerbations of DED. We await further guidance before revisiting our estimates on NCX-4251 but we believe it could be possible, based on FDA feedback, for the company to shift the NCX-4251 development focus from acute exacerbations of blepharitis, to acute exacerbations of DED. It is not surprising a corticosteroid-based product such as NCX-4251 could provide benefit for DED, given that inflammation is a well-known contributor to the disease, and we note that Eyesuvis, a formulation of corticosteroid loteprednol, was approved in Q420 for the short-term treatment of DED. The DED market could provide a substantial opportunity for NCX-4251, as this market is estimated to be worth c $5bn worldwide by Research and Markets and Fortune Business Insights, and three drugs (Restasis, Xiidra and Cequa) have been estimated to account for c $1.5bn in combined total revenue.
Nicox
www.edisongroup.com
viralic
Forumer storico
attendo 1 euro !!!
viralic
Forumer storico
mercati in rimbalzo ?.....vedo segni rossi sugli indici biotech.....e il peggio deve ancora venire. rimbalzino del gatto morto....
Jazalde
Forumer storico
Mica ci manca tanto poi è chiaro a quel punto fallimento.
Si chiude a 1euro, significa la fine di tutto visto che è in pratica zero
Jazalde
Forumer storico
Si ma intanto il cessnicox non fa neanche quelli di rimbalzo....i fondi penso siano già scappati
